Preparation of I-131-Pyrimethamine and evaluation for scintigraphy of experimentally Toxoplasma gondii-infected rats

Basit Öğe Kaydı
dc.contributor.authorInceboz, Tonay
dc.contributor.authorLambrecht, Fatma Yurt
dc.contributor.authorSurucu, Erdem
dc.contributor.authorYilmaz, Osman
dc.contributor.authorYavasoglu, Altug
dc.contributor.authorDurkan, Kubra
dc.contributor.authorBaykara, Basak
dc.contributor.authorBekis, Recep
dc.contributor.authorUner, Ahmet
dc.date.accessioned2019-10-27T21:41:53Z
dc.date.available2019-10-27T21:41:53Z
dc.date.issued2013
dc.departmentEge Üniversitesien_US
dc.description.abstractWe aimed to assess the ability of I-131-Pyrimethamine scintigraphy to detect the lesions of Toxoplasma gondii infection. An experimental model of toxoplasmosis was developed. The presence of toxoplasmosis was confirmed 60 days after implantation. Pyrimethamine was radioiodinated with I-131. The radioligand was validated by the requisite quality control tests to check its radiolabeling efficiency, in vitro stability and radiochemical purity etc. I-131-Pyrimethamine (specific activity: 7.08 MBq/mu mol) was injected intravenously into the tail vein of the control and infected rats. Static whole body images of the rats were acquired under the gamma camera at 5 min, 45 min, 2 h, 6 h, and 24 h following the intravenous administration of the radioactivity (3.7 MBq/rat). Then the scintigraphic data were analyzed both visually and semiquantitatively. Regions of interest (ROIs) were drawn over the organs (thyroid, stomach, liver, bladder, and soft tissues) to calculate the ratios of the radiotracer in infected vs. control rats. The mean ratio of radiotracer in infected/control rats in the liver and diaphragm was over 1 at 45 min which persisted till 24 h. In conclusion, I-131-Pyrimethamine may be useful agent for diagnosis toxoplasmosis especially involving liver and diaphragm, needs further preclinical validation before being extended for use in clinical applications.en_US
dc.identifier.doi10.3109/1061186X.2012.736999en_US
dc.identifier.endpage179en_US
dc.identifier.issn1061-186X
dc.identifier.issue2en_US
dc.identifier.pmid23113799en_US
dc.identifier.startpage175en_US
dc.identifier.urihttps://doi.org/10.3109/1061186X.2012.736999
dc.identifier.urihttps://hdl.handle.net/11454/46770
dc.identifier.volume21en_US
dc.identifier.wosWOS:000314475400006en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherInforma Healthcareen_US
dc.relation.ispartofJournal of Drug Targetingen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectToxoplasma gondiien_US
dc.subjecttoxoplasmosisen_US
dc.subjectWistar raten_US
dc.subject131I-Pyrimethamineen_US
dc.subjectradionuclide imagingen_US
dc.titlePreparation of I-131-Pyrimethamine and evaluation for scintigraphy of experimentally Toxoplasma gondii-infected ratsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu